Biosimilar Antibodies are antibodies sharing identical active biological components with the original therapeutic antibodies, serving as positive controls for drug efficacy evaluation in scientific research and supporting functional validation of target proteins.
Mosunetuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3ε), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing.
Ravulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting C5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment, Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year, Label.
Tralokinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL13, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tralokinumab is under investigation for the treatment of Alopecia Areata. Tralokinumab has been investigated for the treatment of Asthma.
Nadecnemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting GFRA3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Racotumomab is a monoclonal antibody biosimilar expressed in CHO cells, targeting Idiotope of anti-(N-glycolylneuraminic acid (NeuGc, NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Racotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
Lulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD28, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lulizumab pegol is under investigation in clinical trial NCT02843659, Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome.
Ocaratuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MS4A1/CD20, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Andecaliximab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MMP9, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Cibisatamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/CEACAM5, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Cibisatamab (CEA-TCB) is a T cell bispecific antibody that binds carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has a single CD3ε chain binding site and two CEA binding sites on T cells (it regulates the binding affinity to cancer cells with high expression of CEA on the cell surface). This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation, cytokine secretion and release of cytotoxic particles are triggered by binding to CEA on the surface of cancer cells and CD3 on T cells.
Pacmilimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD274, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Suppliers
Request a product
Please provide the required information below so that we can quickly source your products.
